With only 1 in 5 donated lungs currently considered suitable for use, the introduction of the XVIVO Perfusion System for a 4-year period while evidence is generated, could benefit hundreds of NHS ...

Thousands of people in England with a type of chronic heart failure are eligible for a new treatment option following our final draft guidance that recommends finerenone for adults with chronic heart ...

Gavin Redhead, a patient advocate, tells us how heart failure healthtech recommended by NICE helped transform his life.

When a decision is made to prescribe antibiotics, the shortest course that is likely to be effective should be prescribed to reduce the risk of antimicrobial resistance and adverse effects. Short ...

NICE is unable to make a recommendation on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen (PSMA)-positive hormone-relapsed metastatic prostate cancer in ...

Independent committees develop our recommendations. NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers.

Elinzanetant for treating moderate to severe vasomotor symptoms associated with menopause ID6359 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and ...

There are different ways to get involved in NICE’s work and help us to improve NHS and care services for other people – either those who are like you, or those communities you represent as part of a ...

Evidence-based recommendations on lorlatinib (Lorviqua) for treating ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor in adults. Lorlatinib is also ...

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living ...

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...